![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Nastech Announces RNAi Therapeutics-Based RA Study Collaboration
Nastech Announces RNAi Therapeutics-Based RA Study Collaboration
Nastech Pharmaceutical has entered into a clinical research collaboration with the Mayo Clinic to evaluate Nastech's RNA interference (RNAi)-based therapeutic formulations in immune cells from patients with rheumatoid arthritis (RA) for the purpose of selecting a candidate for preclinical and clinical development.
The collaboration will involve the measurement of a series of inflammatory cytokines, including human tumor necrosis factor alpha (H-TNF-alpha), in serum from patients with RA and the screening of proprietary formulations that contain siRNA sequences together with Nastech's novel delivery excipients for H-TNF-alpha knockdown in immune cells collected from these patients.
These formulations are designed to be given systemically and to halt the production of H-TNF-alpha, a protein that is over-expressed in rheumatoid arthritis and that plays an important role in disease pathology.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct